Sacubitril/valsartan for chronic heart failure: its future potential | Zendy

Chaplin Steve | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Sacubitril/valsartan for chronic heart failure: its future potential

Author(s) -

Chaplin Steve

Publication year - 2016

Publication title -

prescriber

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.106

H-Index - 3

eISSN - 1931-2253

pISSN - 0959-6682

DOI - 10.1002/psb.1514

Subject(s) - medicine , valsartan , sacubitril , heart failure , sacubitril, valsartan , ejection fraction , cardiology , angiotensin receptor , neprilysin , pharmacology , angiotensin ii , intensive care medicine , receptor , blood pressure , biochemistry , chemistry , enzyme

Sacubitril/valsartan (Entresto), a combined neprilysin inhibitor/angiotensin II‐receptor antagonist for the treatment of chronic heart failure with reduced ejection fraction, was launched in the UK in January. The phase 3 clinical trial PARADIGM‐HF established its efficacy in chronic heart failure but what is its future place in therapy, according to the latest guidelines and research?

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research